Results 141 to 150 of about 6,419 (213)

Disparate SARS-CoV-2 Infection Outcomes Abound, but What Makes SARS-CoV-2 Bound for Rebound? [PDF]

J Infect Dis
Sheahan TP.
europepmc   +1 more source

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases. [PDF]

Virol J
Su G, Gao F, Yang M, Wang L, Liang L, Li S, Li G, Han N, Li G, Qian G, Zhang S, Luo H, Zhang D, Liang H, Ren Z.   +14 more
europepmc   +1 more source

Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters. [PDF]

Nano Res
Cui Z, Liu T, Bacon R, Zhao Y, Everitt JI, Yan J, Chen L, Huang J, Wang H, Dong Y, Jin VX, Liu SL, Wang Q.   +12 more
europepmc   +1 more source

Analysis of California Senate Bill 1473: COVID-19 Therapeutics [PDF]

, 2022
California Health Benefits Review Program
core  

Candexch algorithm-enhanced chemometric determination of a novel anti-COVID-19 therapeutics in plasma and paxlovid formulation using advanced multivariate modeling: a sustainability-centered bioanalytical approach. [PDF]

BMC Chem
Abbas AEF, Talib NFA, Elghobashy MR, Al Kamaly O, Halim MK.   +4 more
europepmc   +1 more source

Paxlovid-induced Tacrolimus Toxicity in a Renal Transplant Recipient [PDF]

Doughty, Reece
core  

\u27The Perfect Shouldn\u27t Be the Enemy of the Good\u27 — What Canada Can Do Today, Tomorrow & Next Week to Enhance Equitable Access to COVID-19 Biopharmaceutical Interventions [PDF]

, 2022
Herder, Matthew
core  

Bio-inspired chemometric methods for simultaneous UV spectrophotometric determination of molnupiravir, nirmatrelvir, and favipiravir in pharmaceutical formulations and environmental samples. [PDF]

Sci Rep
Abdelzaher AM, Al Kamaly O, Rahman MAA.
europepmc   +1 more source

Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments. [PDF]

J Antimicrob Chemother
Matteini E, Pinnetti C, Frondizi F, Rando E, Chiuchiarelli M, Metafuni E, Mastrorosa I, Alma E, Mazzotta V, Santangelo R, Marchetti S, Sanguinetti M, Sica S, Torti C, Antinori A, Cingolani A.   +15 more
europepmc   +1 more source

SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations. [PDF]

Viruses
Soares VC, Moreira IBG, Dias SSG.
europepmc   +1 more source